Yesterday the government in Rome decided that Spinraza will be offered in Italy to all those with spinal muscular atrophy.
This way Italy became the first country in the European Union where Spinraza, the first-ever registered medicine for SMA, will be available through the national health system to all people with SMA irrespective of age, functional level or SMA type diagnosis. We are aware such a success involved significant effort and wish to congratulate the Italian SMA community on it.
Our TreatSMA group is striving that our UK SMA Community also has broad access to this lifesaving drug though the NHS.
